Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.46 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6538152 | 0.93 | CXCR4 (0.52) | HSD17B10ANPEPERAP2RAD52CYP3A4 | |
| SCHEMBL13478087 | 0.88 | HSD17B10 (0.38) | HSD17B10ANPEPERAP2RAD52CYP3A4 | |
| SCHEMBL1306352 | 0.88 | CXCR4 (0.46) | HSD17B10ANPEPERAP2RAD52CYP3A4 | |
| SCHEMBL14431493 | 0.84 | — | — | |
| SCHEMBL5748707 | 0.80 | — | — | |
| SCHEMBL1307631 | 0.80 | CARM1 (0.50) | POLBALDH1A1GNAI3GNAO1GNAI1 | |
| SCHEMBL845511 | 0.80 | HSD17B10 (0.57) | HSD17B10ANPEPERAP2RAD52CYP3A4 | |
| SCHEMBL6007445 | 0.78 | CHRM5 (0.36) | HSD17B10ANPEPERAP2RAD52CYP3A4 | |
| SCHEMBL19981892 | 0.78 | CARM1 (0.48) | MEN1KMT2APOLBALDH1A1L3MBTL1 | |
| SCHEMBL348039 | 0.78 | CARM1 (0.48) | MEN1KMT2APOLBALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-07-07 | — | — | US | claimed |
| WO-2010014798-A2 | PYRIMIDOTRIAZINEDIONES AND PYRIMIDOPYRIMIDINEDIONES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-02-04 | — | — | WO | claimed |
| EP-0649893-B1 | Adhesive tape for electronic parts and liquid adhesive | TOMOEGAWA PAPER CO LTD (JP) | 1998-05-20 | — | — | EP | claimed |
| US-5500294-A | MODIFIED ACRYLONITRILE-BUTADIENE COPOLYMER | TOMOEGAWA PAPER CO., LTD. (JP) | 1996-03-19 | — | — | US | claimed |
| EP-0649893-A1 | Adhesive tape for electronic parts and liquid adhesive | TOMOEGAWA PAPER CO. LTD. (JP) | 1995-04-26 | — | — | EP | claimed |
| JP-7130772-A | — | — | None | — | — | JP | disclosed |
| JP-8333553-A | — | — | None | — | — | JP | disclosed |
| JP-7126592-A | — | — | None | — | — | JP | disclosed |
| JP-7126591-A | — | — | None | — | — | JP | disclosed |
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-11518871-B2 | Blends of polyolefins with functionalized polybutadienes | BRASKEM AMERICA, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| CN-115427032-A | Pharmaceutical composition and use thereof | 浙江养生堂天然药物研究所有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-4990507-A | Cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-05 | — | — | US | disclosed |
| US-4931453-A | CARDIOVASCULAR, HYPOTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-06-05 | — | — | US | disclosed |
| US-4863942-A | Novel resorcinol ethers and anti-inflammatory and anti-allergic use thereof | CIBA-GEIGY CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4857527-A | HYPOTENSIVE, ANTISCHEMIC AGENT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| US-4831030-A | FOR CEREBROVASCULAR DISEASES; HYPERTENSIVE AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-05-16 | — | — | US | disclosed |
| EP-0311322-A2 | Pyridine or pyridazine derivatives as cardio-protective agents and for the treatment of ischemic disease, and process for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-12 | — | — | EP | disclosed |
| EP-0228845-A2 | N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-07-15 | — | — | EP | disclosed |
| EP-0165897-A2 | Resorcin ethers | CIBA-GEIGY AG (CH) | 1985-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181524-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TCF4, TCF7L2, CTNNB1 | HSD17B10 1725/4885ANPEP 4721/4885ERAP2 3830/4885 |
| US-20110166144-A1 | Pyrimidotriazinediones and Pyrimidopyrimidinediones and Methods of Using the Same | DPYD, TYMP, DHFR | HSD17B10 962/4885ANPEP 1232/4885ERAP2 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.